2nd DZHK Conference on Translational Medicine
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) | German Centre for Cardiovascular Research
Main Office: Oudenarder Straße 16; 13347 Berlin
How does research reach the patient? Scientists and physicians from every medical specialty all over the world ask themselves this question. Particularly widespread diseases like dementia, cardiovascular diseases or cancer pose a significant challenge to the ageing society. The German Centre for Cardiovascular Research (DZHK) is hosting the 2nd DZHK Conference on Translational Medicine under the slogan “Paving the way to new therapies” on 9th and 10th January 2019 in Berlin.
Confirmed Speakers (selection):
For more visit: conference2019.dzhk.de/program/confirmed-speakers/
• Jens Deerberg-Wittram, Executive Director, Boston Consulting Group, Berlin
• Gary Gintant, Research Fellow, AbbVie Deutschland GmbH & Co. KG, Berlin
• John Gray, Chief Science Officer and Senior Vice President of Research & Development, Audentes Therapeutics, San Francisco, USA
• Craig January, Professor in the Department of Medicine in the Division of Cardiovascular Medicine at the University of Wisconsin-Madison, School of Medicine and Public Health, USA
• Hongliang Li, Director, Cardiovascular Research Institute of Wuhan University, China
• Pierluigi Nicotera, Scientific Director and Chairman of the Executive Board, German center for Neurodegenerative Diseases (DZNE)
• Graziella Pellegrini, Full professor of Cell Biology, Department of Surgical, Medical Odontoiatry and Morphological Sciences, University of Modena e Reggio Emilia, Modena, Italy
• Benajmin L. Prosser, Dept. of Physiology, University of Pennsylvania Perelman School of Medicine
• Michaela Sharpe, Head of Clinical Development, Cell and Gene Therapy Catapult, London
• Holger Stark, Director, Department of Structural Dynamics, Max Planck Institute for Biophysical Chemistry, Göttingen
• Martin Ungerer, Chief Medical Officer, advanceCOR GmbH
• Jérôme van Biervliet, Head of Business Development, VIB - Vlaams Instituut voor Biotechnologie, Ghent, Belgium
• Kenneth Walsh, Boston University School of Medicine, USA
